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Abstract: The relationship between immune responses to self-antigens and autoimmune 
disease  is  unclear.  In  contrast  to  its  animal  model  experimental  autoimmune 
encephalomyelitis (EAE), which is driven by T cell responses to myelin antigens, the target 
antigen  of  the  intrathecal  immune  response  in  multiple  sclerosis  (MS)  has  not  been 
identified.  Although  the  immune  response  in  MS  contributes  significantly  to  tissue 
destruction, the action of immunocompetent cells within the central nervous system (CNS) 
may also hold therapeutic potential. Thus, treatment of MS patients with glatiramer acetate 
triggers a protective immune response. Here we review the immunopathogenesis of MS 
and some recent findings on the mechanism of glatiramer acetate (GA).  
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1. Introduction 
Autoimmunity can be defined as an adaptive immune response directed against the body’s own 
tissues. At the beginning of the twentieth century, the German physician Paul Ehrlich coined the term 
“horror autotoxicus” arguing that the normal body would never mount an immune response against its 
own tissue. According to this view, any autoimmune reaction was destructive and connected to human 
disease. We now know that the causal relationship between autoimmune reactions and autoimmune 
diseases is more complex.  
It is estimated that about 20–50% of the T cell and B cell receptors created during receptor gene 
recombination are self-reactive [1]. Although most T and B cells carrying such self-reactive receptors 
are deleted during maturation, a high frequency of autoreactive T cells, B cells and autoantibodies is 
present in the normal repertoire without causing disease. Indeed, it is proposed that recognition of self 
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is essential for survival of naï ve lymphocytes and that it can enhance reactivity to foreign antigen [2], 
that it may regulate the extent and duration of immune responses [3], and that autoantibodies can 
contribute to the clearance of damaged tissue [4]. Furthermore, recognition of self-proteins in the 
absence of costimulation is important for the maintenance of immunological tolerance [5]. 
1.1. Protective autoimmunity in the central nervous system 
Studies in rodents have demonstrated an essential role for regulatory T cells in the reduction of 
injury after stroke [6,7]. On the other hand, observations in a model for crush injury to the optic nerve 
have  shown  that  the  same  myelin  basic  protein  (MBP)  specific  T  cells  that  cause  experimental 
autoimmune  encephalomyelitis  (EAE)  in  mice  also  can  have  a  protective  function  by  reducing 
secondary degeneration of neurons after primary injury to the optic nerve or spinal cord [8,9]. This 
effect was shown to be specific for T cells reactive with central nervous system (CNS) antigens, as T 
cells with other specificities did not confer protection even though they were shown to home to the 
injury  site  [8].  A  follow-up  study  demonstrated  that  suppression  of  the  autoimmune  reaction  by 
tolerance  induction  to  MBP  or  by  the  injection  of  CD4
+CD25
+  regulatory  T  cells  reduced  the 
protective effect of MBP specific T cells [10]. Thus, a degree of autoimmunity was required to confer 
protection. These observations have implicated T cells as important mediators of CNS neurogenesis, 
the process by which neuronal precursor cells give rise to new neurons in certain areas of the brain 
[11,12]. Accordingly, it was shown that T cell deficient mice displayed decreased neurogenesis from 
endogenous  precursor  cells  compared  to  normal  mice,  and  that  this  could  be  partly  restored  by 
reconstitution of the T cell pool [13].  
The  protective  effect  of  CNS-reactive  T  cells  most  likely  involves  activation  of  local  antigen 
presenting cells (APCs) present at the injury site [14,15]. It has been demonstrated that activation of 
microglia  by  either  the  Th1  cytokine  IFN-γ  or  the  Th2  cytokine  IL-4  induced  neuronal  and 
oligodendroglial differentiation from adult neuronal precursor cells [16], and thus hypothesized that 
the release of cytokines may serve a function in the recruitment of neuronal precursor cells to the 
injury site. In support of this, neuronal precursor cells layered onto hippocampal slice cultures were 
shown to migrate towards sites treated with inflammatory stimuli, such as TNF-α or IFN-γ [17]. This 
was dependent upon cytokine-induced upregulation of chemo-attractants. Differentiation of progenitor 
cells arriving at the injury site may in part be mediated by growth factors. Activated microglia and 
macrophages have been shown to secrete a variety of growth factors in vivo [18], and may reciprocally 
induce the production of growth factors in other cells [13]. Furthermore, activated human T cells, B 
cells  and  monocytes  in  inflammatory  MS  lesions  as  well  as  myelin  oligodendrocyte  glycoprotein 
(MOG) reactive T cells from healthy individuals express nerve growth factors [19,20].  
1.2. Autoimmune diseases  
The  relation  between  benign  autoimmunity  and  the  progression  and  establishment  of  an 
autoimmune  disease  is  unclear.  An  autoimmune  disease  can  be  organ  specific,  such  as  in  type  1 
diabetes  and  multiple  sclerosis  (MS)  or  systemic  such  as  in  systemic  lupus  erythematosus  and 
Sjogren’s  syndrome  and  is  characterized  by  a  chronic  adaptive  immune  response  directed  against  
self-tissue. About 3–5% of the world’s population is affected by an autoimmune disease with women Toxins 2010, 2                        
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accounting for 78% of cases [21]. It is believed that a combination of risk-associated polymorphisms 
in  immunoregulatory  genes,  infectious  agents  and  other  environmental  triggers  contribute  to  the 
initiation and propagation of disease [22,23]. Thus, a few examples of human autoimmune diseases 
induced by defined microbes exist, such as rheumatic fever and Guillain-Barré  syndrome. These are 
thought  to  arise  from  antigenic  mimicry  between  the  infectious  agent  and  human  tissue  triggered 
during the initial inflammatory response. For the majority of human autoimmune diseases, however, 
the link to infection remains circumstantial. This may be due to the time lag between infection and 
establishment of disease and the potential contribution of subclinical infections.  
2. Immune Surveillance of the Central Nervous System 
The  CNS  is  comprised  of  the  brain  and  spinal  cord,  surrounded  by  three  layers  of  meningeal 
membranes. The blood brain barrier (BBB) is a feature of the cerebral vasculature, which restricts 
access  of  ions  and  other  solutes  present  in  the  blood  into  the  brain  parenchyma.  The  anatomical 
structure of the BBB comprises two cell layers, which are separated by the perivascular space. One is 
formed by endothelial cells lining the brain capillaries and an underlying basement membrane, and the 
other is formed by astrocytic foot processes and their parenchymal basement membrane. Unlike other 
tissues, the endothelial cells of the BBB display no fenestration and are connected by tight junctions, 
which efficiently restrict the traffic of molecules and cells in and out of the brain. The cerebrospinal 
fluid (CSF) bathes the brain and is produced from arterial blood by the choroid plexus. It flows from 
the ventricles of the brain into the subarachnoid space located between the arachnoid and the pial 
membrane and is eventually absorbed into the venous circulation. The CSF communicates with the 
interstitial fluid of the brain through the perivascular spaces. Due to the lack of tight junctions in the 
ependymal linings of the ventricles, small hydrophilic molecules as well as proteins diffuse freely 
between the CSF and brain interstitium (reviewed in [24]). 
Under physiological conditions, immune cells enter the CNS at a very low level for the purpose of 
immune surveillance [25,26]. In contrast, during inflammatory diseases such as MS, activated cells 
readily traverse the inflamed BBB [27]. CNS fluids continuously drain into cervical lymph nodes, 
ensuring communication with the peripheral lymphoid system, but the absence of secondary lymphatic 
structure, the low expression of major histocompatibility complex (MHC) class II molecules and the 
lack of dendritic cells (DCs) in the CNS have questioned how immune surveillance of the brain takes 
place under physiologic conditions [25,26]. 
Perivascular cells within the subarachnoid space probably play a key role in immune surveillance. It 
is suggested that activated memory cells enter the CSF from the systemic circulation and monitor the 
subarachnoid space under physiologic conditions [26]. This is strongly supported by observations in 
EAE  where  parenchymal  inflammation  and  disease  onset  is  preceded  by  inflammation  and 
accumulation of Th17 polarized CD4+ T cells in the subarachnoid space [28,29]. Furthermore, it was 
recently demonstrated that Th17 cells expressing the chemokine receptor (CCR)6 were allowed access 
into the perivascular space through the choroid plexus by interaction with the CCR6 ligand, CCL20 
[30]. This step triggered and was indispensable for a second wave of inflammation mediated by T cell 
infiltration through the BBB. CCR6 was found to be constitutively expressed by cells of the choroid Toxins 2010, 2                        
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plexus also in humans, and the entry of Th17 cells into the CSF was suggested to control immune 
surveillance of the CNS during physiologic condition.  
Migration of cells across the blood brain barrier 
The migration of mononuclear cells across an inflamed BBB is a two-step process, which first 
requires entry across the endothelial cell layer and its basement membrane into the perivascular space. 
Several  adhesion  molecules,  including  activated  leukocyte  cell  adhesion  molecule,  intracellular 
adhesion molecule, vascular cell adhesion molecule (VCAM)-1, α4-integrin and laminins seem to be 
selectively  involved  in  the  adhesion  and  transmigration  of  T  cells  (reviewed  in  [31]).  Adhesion 
molecules are believed to aggregate in microdomains on the endothelium, so-called transmigratory 
cups, which guide the migration of lymphocytes across inflamed cerebral vessels. The monoclonal 
antibody  (mAb)  natalizumab,  used  in  the  treatment  of  MS,  efficiently  inhibits  the  infiltration  of 
lymphocytes into the brain by blocking the VCAM-1-ligand, α4β1-integrin [31]. Furthermore, T cell 
transmigration could be selectively inhibited by laminin-α5, an adhesion molecule expressed on the 
endothelial basement membrane [32].  
To  reach  the  brain  parenchyma  from  the  perivascular  space  leukocytes  must  traverse  the 
parenchymal basement membrane and the glia limitans, a thick layer of astrocytic processes that seals 
the entire surface of the CNS. The molecular mechanisms facilitating this step are less defined, but are 
thought to involve secretion of matrix metalloproteinases (MMPs) by perivascular macrophages or 
DCs. Hence, mice were made resistant to EAE by deletion of MMP-2 and MMP-9, and T cells were 
trapped in the perivascular space [33]. Thus, cells that gain access to the perivascular space through 
interaction with inflamed brain endothelium may only traverse the glia limitans into the parenchyma if 
they recognize their cognate antigen presented by perivascular APCs [34,35]. Also the strength of 
lymphocyte reactivation in the perivascular space may determine migration into the brain parenchyma 
[36]. MHC expression by endothelial cells may also play a role in the recruitment of antigen specific T 
cells, as recently demonstrated for the migration of CD8
+ T cells across the BBB [37]. Finally, T cells 
that infiltrate the brain parenchyma may interact with resident microglia, which in response to CNS 
inflammation acquire a macrophage-like phenotype with increased expression of costimulatory and 
adhesion molecules [38].  
3. Multiple Sclerosis 
MS was first described in 1868 by Jean-Martin Charcot [39], but early reports of people suffering 
distinct neurological symptoms analogous to MS date back to the middle ages [40]. Today MS has a 
prevalence that generally ranges from 2–150 per 100,000, although this can be significantly higher in 
certain  regions.  The  etiology  of  MS  is  complex  and  involves  genetic  and  environmental  
factors [41–43]. 
3.1. Clinic  
MS  usually  presents  with  a  clinically  isolated  syndrome,  a  neurological  episode  suggestive  of 
inflammation and demyelination, but not sufficient by itself to qualify for an MS diagnosis. In the Toxins 2010, 2                        
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majority  of  patients,  disease  typically  evolves  with  irregular  relapses  followed  by  more  or  less 
complete remission. The use of magnetic resonance imaging allows visualization of affected CNS 
sites. Radiological evidence of inflammation disseminated in time and space is part of the revised 
diagnostic criteria for MS [44]. At the onset of disease, the majority of patients follow a relapsing-
remitting  (RR)  course,  whereas  in  about  15%  of  patients,  disease  progresses  without  intermittent 
relapses in what is referred to as primary progressive MS [45]. Progression of disease in most RRMS 
patients will over time also be devoid of remissions and evolve into a secondary progressive course 
[46],  where  the  most  important  clinical  feature  is  the  progression  of  disability  in  the  absence  
of relapses.  
3.2. Etiology 
Clustering of MS cases within families and the sharp decline in concordance with increasing genetic 
distance demonstrate the genetic contribution to MS [41]. The strongest genetic association to MS is 
found within the human leukocyte antigen (HLA) complex. The HLA-DRB1*1501 allele is thought to 
confer  the  primary  association  in  Caucasians  and  Afro-Americans  [47,48].  Lately,  genome  wide 
association  studies  have  pointed  out  an  association  between  MS  and  immunoregulatory  genes 
encoding IL-2 and IL-7 receptor α chains, which are associated with activation and homeostasis of T 
cells [49,50].  
Several observations demonstrate the environmental contribution to MS risk: (i) the relative low 
concordance rate in monozygotic twins, (ii) the influence on MS risk by migration to areas of low or 
high MS prevalence, and (iii) the increase in female:male sex ratio observed over time [42,43]. Both 
infectious  and  non-infectious  factors,  such  as  vitamin  D  and  smoking,  have  been  implicated  by 
epidemiological evidence. It seems that environmental factors in childhood contribute to MS risk and a 
study on adoptees have demonstrated that environmental factors in MS operate on a population basis 
and not in the microenvironment [51].  
Of  many  possible  infectious  agents  suggested  to  confer  MS  risk,  Epstein-Barr  virus  (EBV)  is 
supported by the strongest epidemiological evidence. MS risk is higher in individuals with a past 
history of infectious mononucleosis, and a temporal increase in serum titres of antibodies to EBV has 
been shown to correlate with the onset of MS later in life [52]. The functional relevance of EBV in MS 
is  supported  by  a  higher  frequency  of  EBV  specific  T  cell  in  MS  patients  [53]  and  by  the 
demonstration of MBP specific T cells that cross react with EBV-proteins [54,55]. Furthermore, strong 
CD8
+ T cell responses to EBV can be detected in cases of early MS [56]. However, the reported 
identification of EBV-infected B cells in white matter lesion in MS [57] has been challenged by the 
inability of other groups to reproduce these findings [58,59] leaving it controversial as to whether EBV 
contributes directly to CNS pathology.  
3.3. Pathogenesis  
Lessons from EAE have guided much of the research in MS and formed the long-held view that 
myelin specific CD4
+ cells play a key role in MS. EAE is caused by a direct attack on myelin proteins 
mediated by myelin specific CD4
+ T cells [60]. EAE can be induced in susceptible strains of rodents 
and  nonhuman  primates  through  immunization  with  myelin  proteins  or  peptides  emulsified  in Toxins 2010, 2                        
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complete  Freund’s  adjuvant  or  by  adoptive  transfer  of  activated  myelin  specific  CD4
+  T  cells. 
Although EAE reflects important pathogenic mechanisms in MS, observations such as a dominance of 
clonally  expanded  CD8
+  T  cells  in  active  MS  lesions,  the  perpetual  intrathecal  production  of 
oligoclonal IgG, and the failure to firmly establish myelin proteins as target antigens in MS underscore 
critical differences in the pathogenesis of human MS and animal EAE [61]. 
The  clinical  benefit  of  blocking  migration  of  lymphocytes  into  the  CNS  or  of  strong 
immunosuppression with mAbs has for the first time provided conclusive evidence for the detrimental 
effect  of  the  immune  response  in  MS  [62,63].  However,  whether  the  immune  response  in  MS  is 
primarily autoimmune or secondary to neurodegeneration elicited by other factors is still not settled. 
According to the autoimmune hypothesis of MS, it is assumed that effector CD4
+ and CD8
+ T cells are 
primed in secondary lymphoid organs through antigen specific T cell-APC interactions [64]. In view of 
recent findings, it may be proposed that reactivation of antigen specific Th17 cells in the perivascular 
space plays a crucial role for the transmigration of other T cell subsets [29,30]. The upregulation of 
adhesion molecules and corresponding ligands by brain epithelium and activated lymphocytes allows 
the migration of activated T cells and B cells across the BBB. It is believed that only those T cells that 
recognize  cognate  antigen  will  be  retained  in  the  brain  [27].  Reactivation  may  occur  by  cross 
recognition of myelin or neuronal antigens, by recognition of an original infectious agent [57] or of 
other antigens present in the brain, such as idiotopes on clonally expanded B cells and IgG molecules 
[65]. Reactivation of T cells triggers parenchymal inflammation, which recruits T cells, B cells, DCs 
and microglia to the site of inflammation. The release of pro-inflammatory cytokines, direct damage 
mediated by MHC class I restricted CD8
+ T cells and indirect damage by MHC class II restricted 
CD4
+ T cells, complement deposition and local activation of microglia and macrophages [66], may all 
have a role in the inflammatory response. The reason why the immune response becomes chronic 
remains unknown, but could be explained by site-specific expression of autoantigens, persistence of 
latent infections, a permissive CNS environment or a combination of these factors. 
3.4. The intrathecal immune response in MS  
A hallmark of the immune response in MS is the formation of isolated areas of inflammation called 
MS lesions. Lesions can appear both in the white and in the grey matter of the brain and are often 
found around the ventricles, in the optic nerve, in the brain stem and in the spinal cord [67]. Tissue 
damage involving grey matter and normal appearing white matter can also be observed [68]. Within 
lesions  the  most  characteristic  pathological  feature  is  demyelination.  Axonal  damage  is  probably 
present from early in the disease process and numerous transected axons can be visualized in active 
lesions [69]. Mononuclear infiltrates of CD4
+ T and CD8
+ T cells, B cells and macrophages are present 
to various extents and are thought to be critical for disease development and progression. Much effort 
has been devoted to analyzing the phenotype of T and B lymphocytes dominating in the intrathecal 
compartment  as  a  means  to  identify  potential  antigens  and  to  understand  the  underlying  
disease process.  Toxins 2010, 2                        
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3.4.1. T cells 
Within the active lesion clonally expanded CD8
+ T cells outnumber CD4
+ T cells, which are more 
polyclonal and often found in the periphery of the lesion [70,71]. By analyzing 22 tissue blocks from 
patients and healthy controls, the majority of T cells in active MS lesions were found to express IL-17 
[72]. Unlike what is described for EAE, both CD4
+ and CD8
+ T cells from MS lesions stained positive 
for IL-17. Their expression of cytolytic granules and their ability to kill neurons in vitro [73] have 
pointed out Th17 cells as a critical subset of T cell in MS [74]. 
T cells within MS lesions display a restricted receptor repertoire [75,76], suggesting that a limited 
number of clones participate in local immune reactions. Furthermore, central memory T cells within 
MS lesions have been shown to lack CCR7 [77], indicating that they had differentiated into effector T 
cells  upon  restimulation  with  antigen.  However,  the  antigen-specificity  of  T  cells  in  MS  remains 
unclear. In light of EAE, the search for an MS target antigen has revolved around myelin peptides, but 
the role of myelin specific T cells in MS is  uncertain. The frequency of MBP specific T cells is 
overlapping in MS patients and controls, although T cells from MS patients seem to display a higher 
frequency of activation markers and tend to belong to the memory pool of T cells [78]. A phase II 
clinical  trial  where  MS  patients  were  immunized  with  an  altered  peptide  ligand  based  on  an 
immunodominant MBP epitope, resulted in clinical exacerbations associated with an increase in the 
frequency of T cells specific for the MBP epitope in the CSF [79]. This suggests that MBP specific T 
cells may cause encephalomyelitis also in humans, but does not pinpoint MBP specific T cells as 
culprits in MS. In a young patient suffering from hyperacute MS, T cell infiltrates were shown to 
display reactivity to myelin proteins [80]. However, earlier attempts to chart the specificity of T cell 
clones isolated from MS lesions have not detected reactivity to MBP or proteolipid protein (PLP) [81]. 
The pathogenic role of myelin specific T cells is further complicated by the therapeutic potential these 
cells may have [82]. 
The  search  for  alternative  antigens  in  MS  has  suggested  the  stress  protein  αB-crystallin  as  a 
potential target. αB-crystallin is a small heat shock protein and one of the most abundantly expressed 
proteins that is found in active MS lesions, but not in normal brain [83,84]. In comparison to a variety 
of  other  myelin  proteins,  which  included  MBP,  PLP  and  MOG,  αB-crystallin  elicited  strong 
proliferative responses in peripheral blood lymphocytes from MS patients. Thus, other potential T cell 
targets in MS may be proteins expressed uniquely in MS brains and not in a normal brain [85]. A 
recent gene expression study of cortical MS lesions and meninges did, however, only identify over 
expression of immunoglobulin (Ig) related genes [86]. 
3.4.2. B cells 
Several observations demonstrate that B cells are involved in the disease process of MS. B cells, as 
well as deposits of Ig and complement, are found within MS lesions [87] and more than 95% of MS 
patients display a perpetual intrathecal synthesis of oligoclonal Ig, which can be visualized as distinct 
oligoclonal bands (OCBs) by isoelectric focusing or agarose gel electrophoresis. The OCBs of MS 
patients are predominantly IgG1. OCBs can also be observed in infectious diseases of the CNS where 
the antigenic target is the infectious etiologic agent [88,89].  Toxins 2010, 2                        
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Analyses of transcribed BCR V genes from CSF and MS lesions have revealed a population of B 
cells  that  is  clonally  expanded,  displays  a  limited  H  chain  repertoire  and  that  contains  numerous 
replacement mutations (reviewed in [90]). These observations suggest that the B cell response in MS is 
an antigen-driven T cell dependent process. Prominent clonal expansion of CSF B cells is an early 
feature of MS, suggesting that antigen-specific B cell responses may be implicated at the onset of 
disease [91,92]. Short-lived plasma blasts are more prevalent in the CSF than mature plasma cells, and 
have  been  suggested  to  be  the  main  effector  B  cell  population  [93,94].  A  comparison  of  the  Ig 
transcriptome  of  B  cells  with  the  corresponding  Ig  proteome  in  the  CSF  of  four  MS  patients 
established that CSF B cells were at least one possible source of the OCBs [95]. However, OCB 
formation  in  CSF  may  also  result  from  B  cell  activation  within  the  CNS  parenchyma.  Efforts  to 
identify the specificity of the main oligoclonal IgG in MS remains a challenge [96].  
Antibodies with reactivity against myelin proteins can readily be detected in the CSF of MS patients 
[97,98]. IgG from CNS tissue was found to contain anti-MOG antibodies in seven of 14 MS patients 
[99], and nine out of 10 antigen binding fragments from clonally expanded CSF B cells from four MS 
patients recognized MBP [100]. However, the pathogenic relevance of myelin specific antibodies in 
MS remains uncertain.  
A  curious  feature  of  MS  is  the  perpetual  intrathecal  production  of  virus  specific  antibodies 
[101,102]. These antibodies are typically directed towards measles, varicella zoster, rota and mumps 
viruses [101,103,104]. They mainly display IgG1 subclass restriction [105] and are also present in 
vaccinated individuals [106]. These virus specific antibodies display an oligoclonal pattern, but are not 
part of the main OCBs and constitute only a small fraction of intrathecally synthesized IgG [89,101]. 
Moreover, clonally expanded CSF B cells cultured in vitro were shown to display specificity for the 
same viruses as that described for intrathecally produced antibodies [107]. The fact that some of these 
antibodies are directed against RNA-viruses that most probably do not persist in the CNS, suggests 
that they are not a result of an ongoing virus specific immune response. 
Whether  the  intrathecal  humoral  immune  response  in  MS  is  pathogenic  or  represents  an 
epiphenomenon has been unclear. However, there are several indications that B cells in MS may play a 
role in the disease process beyond their capacity to produce antibodies. Ectopic lymphoid follicles 
enriched with B cells and plasma cells have been observed in the meninges of patients with secondary 
progressive MS [108], compatible with an ongoing B cell differentiation at least in late stages of the 
disease.  The  formation  of  local  germinal  center-like  structures  has  also  been  described  in  other 
autoimmune conditions [109] and may be a common feature of chronic inflammatory responses. In the 
case of MS, this may suggest that maturation of B cells takes place in the intrathecal compartment. 
This  view  is  supported  by  the  presence  of  centroblasts,  a  B  cell  population  typical  of  secondary 
lymphoid  organs,  in  the  CSF  [110].  In  addition,  antigen  dependent  short-lived  plasma  blasts  are 
common in the CSF [94]. These observations are intriguing in light of the therapeutic potential of 
rituximab  [111].  Rituximab  targets  CD20,  which  is  carried  by  B  cells  at  all  stages  of  B  cell 
differentiation, except for pro-B cells and plasma cells. A near complete deletion of CD20 expressing 
B cells in the CSF and blood was observed in treated patients, who concomitantly experienced a 
marked reduction in clinical attacks and a decrease in the number of lesions. Moreover, following  
24 weeks of rituximab treatment the number of CD3
+ T cells in the CSF was significantly reduced in 
the  majority  of  patients  [112].  However,  the  IgG  concentration  in  CSF,  the  IgG  index,  the  IgG Toxins 2010, 2                        
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synthesis rate and the number of OCBs were not affected [112]. This suggests that the therapeutic 
effect of rituximab is independent of antibody production and that other B cell effector functions are 
involved, such as bystander activation through cytokine secretion or the ability to present antigen to T 
cells [78]. 
4. Glatiramer Acetate in the Treatment of MS 
Although the immune response in MS is predominantly detrimental to the CNS, there seems to be 
protective  elements  as  well.  Most  treatments  for  MS  aim  at  preventing  lymphocyte  migration, 
activation or proliferation, or neurotransmission [113].Glatiramer acetate (GA), one of the first-line 
drugs in the treatment of RRMS, provides an exceptional opportunity to study a T cell response with a 
proven beneficial clinical effect. Although the long term clinical efficacy of GA is questionable, GA 
will be discussed here as an example of immunomodulation and protective immunity in the treatment 
of MS.  
GA is a synthetic copolymer comprised of the four amino acids most frequent in MBP; glutamine, 
alanine, lysine and tyrosine. The original idea was that GA would be sufficiently identical to MBP in 
terms of sequence and antigenicity that it could be used as a substitute for the induction of EAE. 
Administration  of  GA  unexpectedly  showed  the  opposite  effect;  mice  were  protected  against  the 
development of clinical disease [114]. A phase III, multicenter, double blind, placebo-controlled trial, 
which  included  251  RRMS  patients,  demonstrated  a  29%  reduction  in  relapse  rate  compared  to 
placebo in patients who received GA for two years [115,116]. This result was the main basis for the 
subsequent approval by the US federal drug administration of GA for the treatment of MS.  
4.1. Effects on the immune system 
GA binds with high affinity to HLA class II molecules of the DR isotype, and can do so without 
prior processing [117]. GA seems to have a number of effects on APC function, such as a reduction in 
the secretion of pro-inflammatory  cytokines and an  increase in the secretion of anti-inflammatory 
cytokines. This may in turn induce an anti-inflammatory phenotype in GA reactive T cells (reviewed 
in [118]). A GA-induced shift in the cytokine profile of GA reactive CD4
+ T cells towards an anti-
inflammatory phenotype has been demonstrated in patients by comparing the cytokine profile of GA 
reactive blood T cell lines from blood and CSF before and after treatment [119–121]. Additionally, GA 
may lead to anergy-induction of pathogenic lymphocytes [122,123], and restoration of function and 
frequency of regulatory T cells [124–126]. It has become increasingly clear that GA may also affect 
other arms of the immune system such as natural killer cells, CD8
+ T cells and B cells [127–129].  
4.2. Cross reactivity 
Due to similarities in amino acid composition between MBP and GA, cross recognition of MBP has 
been thought to account for the reactivation of GA reactive T cells in the CNS. This has been based 
upon the observations that GA reactive T cells accumulate in the CNS of GA-treated mice [130,131] in 
combination with studies demonstrating cross reactivity between MBP and GA as assessed by cytokine 
secretion [131]. In mice, GA reactive T cells were shown to react to MBP by secretion of IL-4, IL-6 Toxins 2010, 2                        
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and  IL-10  [132]  and  to  target  the  immunodominant  epitope  82–100  of  MBP  by  T  cell  receptor 
antagonism  [133].  The  secretion  of  anti-inflammatory  cytokines  is  thought  to  mediate  bystander 
suppression of nearby pathogenic T cells within the CNS [131]. However, GA is not only efficient in 
MBP-induced EAE, but also in PLP and MOG-induced disease [134,135], suggesting either that cross 
reactivity with MBP is not essential for the therapeutic effect or that cross reactivity is a more general 
phenomenon.  
Studies  using human  T cell lines have  either failed to  detect  cross reactivity between GA and 
myelin proteins [136,137] or reported it as a low frequency or unspecific event [120,121,138,139]. GA 
reactive T cell lines from six of seven patients displayed cross reactivity to random combinatorial 
peptide libraries, including peptides from MBP. Cross reactivity was determined by cytokine secretion 
and was consistent with a degenerative response as no dominantly cross reactive peptide emerged 
[120]. Two other studies reported cross reactivity to MBP by cytokine secretion in 10–25% of GA 
reactive cell lines [139,121]. Cross recognition assessed by proliferation was observed for three of 18 
GA reactive cell lines against MBP in a patient treated with GA for 6 years [138]. Cross reactivity can, 
however, not be faithfully studied in polyclonal T cell lines, which may contain one T cell clone that 
responds to GA and another that responds to a myelin protein. In our lab, none of 20 GA-reactive 
CD4+ T cell clones from blood and CSF cross recognized a panel of overlapping peptides spanning the 
complete sequences of MBP, PLP, MOG, myelin-associated oligodendrocytic basic protein, myelin-
associated glycoprotein, oligodendrocyte myelin glycoprotein, αβ-crystallin, S100β, and 2',3'-cyclic 
nucleotide 3'-phosphodiesterase [119]. This does not exclude that cross reactivity may occur, but rather 
supports that other mechanisms contribute to the efficacy of GA reactive T cell inside the CNS.  
The high frequency of GA reactive T cells in the blood and CSF of treatment-naï ve individuals 
observed by us and others, and the demonstration that the majority of these are recruited from the 
memory pool of T cells [121,138] suggest that GA mimics recall antigens to which the patient has 
been exposed previously. This is not unexpected considering the multitude of epitopes which may arise 
from the random composition of GA. Furthermore, the well-defined degeneracy of T cell receptors 
implies that a low level of random cross reactivity may be expected. Such random cross reactivity may 
account for reactivation of GA reactive cells in a variety of tissues and perhaps contribute to the 
therapeutic potential of GA in inflammatory diseases outside of the CNS [140,141]. Also, it may be 
hypothesized  that  a  persistent  inflammatory  environment  triggers  a  transient  reactivation  of  GA 
reactive T cells in a T cell receptor independent manner, which results in release of anti-inflammatory 
cytokines.  This  may  contribute  to  bystander  suppression  of  local  inflammation  in  MS  and  other 
inflammatory diseases (Figure 1). Toxins 2010, 2                        
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Figure 1. GA may affect several arms of the immune system, including CD4+ and CD8+ T 
cells, B cells, natural killer (NK) cells, regulatory T cells (T regs) and APCs (1). GA 
induces an anti-inflammatory profile in both APCs and T cells and these cell populations 
may reciprocally stimulate each other. The effect on CD4+ T cells is thought to involve 
recognition of GA presented on HLA class II molecules by APCs in peripheral lymphoid 
organs (2). Activated T cells may cross an inflamed BBB and gain access to the CNS (3). 
Within the CNS, reactivation of GA reactive T cells may occur through random cross 
reactivity with CNS peptides presented by CNS resident APCs (4) or in a T cell receptor 
independent  fashion  triggered  by  the  persistent  inflammatory  environment  within  the 
inflamed  CNS  (5).  Reactivation  of  GA  reactive  T  cells  within  the  CNS  may  lead  to 
secretion  of  anti-inflammatory  cytokines,  which  will  dampen  ongoing  inflammation 
through  “bystander  suppression”  (6).  In  addition,  secretion  of  neurotrophic  factors  by 
activated T cells may affect neurogenesis and remyelination in the brain (7). 
 
4.3. Neurotrophic effect 
The therapeutic effect of GA is postulated to involve neuroprotection [118,142]. GA reactive T cell 
lines from MS patients and healthy controls have been shown to display low basal secretion of brain-
derived neurotrophic factor (BDNF), which increased upon stimulation with GA [143,144]. In mice, in 
situ secretion of BDNF by GA reactive T cells correlated with reduced neuronal damage as well as 
increased neuronal proliferation [145], and GA treatment was recently shown to induce remyelination 
in  EAE  mice  and  in  a  toxic  model  of  demyelination  [146,147].  Interestingly,  GA  has  also  been 
demonstrated to suppress the development of some models of amyotrophic lateral sclerosis, which is a 
neurodegenerative disease caused by mutation in the superoxide dismutase (SOD) gene with only 
moderate and secondary T cell infiltration [148]. It is, however, not evident that this effect is mediated 
by the secretion of neurotrophic factors, as SOD1 mutants also display profound immunodeficiency 
that could be affected by GA treatment [149]. Importantly, secretion of BDNF is not restricted to GA Toxins 2010, 2                        
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reactive T cells, but seems to be a more general feature of activated immune competent cells. Thus, T 
cells, B cells and monocytes have all been demonstrated to secrete BDNF in vitro and in inflammatory 
brain lesions [19]. This may suggest that the daily injection of GA promotes BDNF secretion as a 
result of a continuous activation of GA reactive peripheral T cells, which subsequently gain access to 
the CNS [150] (Figure 1).  
Taken together, studies in mice suggest that GA has the ability to support growth of nervous tissue 
[145,147,118]. To which extent this applies also in humans and the relevance in MS is less clear and 
needs further attention using human cells and tissue. 
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